The committee considered 5 separate charges against Dr Radev, relating to his treatment of a Yorkshire Terrier and Shih Tzu cross called Pickles at a Vets4Pets veterinary practice in Oxford between 5 October 2015 and 1 November 2015. The charges related to Dr Radev failing to provide adequate and/or appropriate care to the animal and failure to keep detailed clinical records.
After hearing the evidence from Dr Radev and the complainant, the College submitted that it wished to withdraw charges 1(i) and 1(ii) on the basis of insufficient evidence. In addition, Dr Radev had already admitted charges: 1(iii)(b), 1(iv)(d), 1(v), 4(i)(a) and 4(ii)(a) but denied the remaining charges. Of these remaining charges the Committee found charges 1(iv)(a), 2(i), 2(iv), 3(i) and 3(ii) proven with the rest not being proven.
The charges admitted or found proven were that Dr Radev:
(1) On 5 October 2015, failed to provide adequate and/or appropriate care and/or treatment to Pickles, more particularly in that he:
(iii) Failed to offer and/or undertake adequate investigations into Pickles’ condition, more particularly in that he failed to offer and/or undertake:
(b) urine tests;
(iv) Failed to put in place and/or document an adequate management plan for Pickles, more particularly in relation to:
(a) adequate direction and/or advice regarding a review of Pickles’ condition within a clearly defined number of days;
(d) collection of urine at home for analysis on review at the practice;
(v) Having noted that he suspected renal disease, prescribed meloxicam when the same was contraindicated for dogs with renal disease;
(2) On 28 October 2015, failed to provide adequate and/or appropriate care and/or treatment to Pickles, more particularly in that he:
(i) Failed to take and/or record an adequate history from Mrs Pancott in relation to Pickles’ condition and/or clinical signs since 5 October 2015;
(iv) Failed to provide adequate direction and/or advice regarding a date for a review of Pickles’ condition within a clearly defined number of days;
(3) On 30 October 2015, having been informed that Mrs Pancott had telephoned the practice with concerns about Pickles, including blood in the faeces;
(i) Failed to note the matter in Pickles’ medical records;
(ii) Failed to take sufficient steps to obtain more information from Mrs Pancott or to ensure that Mrs Pancott was advised to seek veterinary attention for Pickles in relation to her concerns;
(4) On 1 November 2015, failed to provide adequate and/or appropriate care and/or treatment to Pickles, more particularly in that he:
(i) Failed to interpret the blood tests adequately and/or take appropriate and adequate action in relation to the results of those blood tests, more particularly with regards to:
(a) blood glucose;
(ii) Failed to offer and/or undertake adequate investigations into Pickles’ condition, more particularly in that he failed to:
(a) offer and/or undertake urine tests.
In considering these charges the Disciplinary Committee found that only charge 4(ii)(a) – namely the failure to correctly interpret and act upon the results of a blood glucose test – amounted to serious professional conduct with the rest not passing the threshold of disgraceful conduct in a professional respect. The Committee did not consider that in addition the cumulative effect of all the proven charges taken together amounted to serious professional misconduct.
In relation to the cumulative effect of all the proven charges Professor Alistair Barr, chairing the Committee and speaking on its behalf, said: "The Committee noted that Dr Radev had made errors in relation to one patient but on four separate occasions. These were, for the most part, individual failures at the lower end of the scale of seriousness. Taking into account all of the failings, the Committee in its judgement did not consider that the nature and number of errors and the period of time over which they took place justified a cumulative finding of disgraceful conduct."
In considering the sanction for Dr Radev the Committee took into account a number of mitigating circumstances including the fact that Dr Radev had undertaken suitable training and development in the areas in which he made mistakes, had demonstrated good insight into his conduct and had made some open and frank admissions early on in proceedings. It also considered that the one charge that was found to be serious professional misconduct was a single, isolated mistake linked to Dr Radev’s inexperience.
Professor Barr said: "The Committee considered that taking ‘no further action’ was appropriate and proportionate having considered the history of the case, the Committee’s overall findings and the good reports of Dr Radev’s performance in the two years since the matter which had led to the finding of disgraceful conduct in a professional respect."
The decision to take no further action was also influenced by the length of time it had taken the charges to be heard by the Committee, the positive character references about Dr Radev from professional colleagues and the fact he was unlikely to repeat such conduct in the future.
Tablets are divisible into 15mg increments to enable accurate titration of dosing, come blister-packed to facilitate dispensing and are liver flavoured to help with compliance.
TVM says that in a first for a phenobarbital generic, Soliphen has proven bioequivalence to the market leading brand, which provides the reassurance of staying on-label when switching from the leading brand is necessary or desirable.
William Peel, Product Manager at TVM UK, said: "Phenobarbital is the only veterinary licensed drug for use in idiopathic and structural epilepsy, benefiting a large proportion of epileptic dogs with an improvement in seizure frequency. As a result, phenobarbital is a mainstay of treatment in epilepsy cases. With Soliphen, we have developed a cost-effective, easier and more accurate solution."
Soliphen is supported with a range of materials for use in practice, including owner booklets on epilepsy and in practice guidelines for the management of status epilepticus and chronic seizure control.
For more information, speak to your local TVM-UK Territory Manager, email: help@tvm-uk.com, visit: www.tvm-uk.com or call: 0800 0385868.
Eurovet Animal Health has launched Vomend, a new veterinary licensed metoclopramide that can be used to treat vomiting and reduced gastro-intestinal motility in both dogs and cats.
Eurovet says that for years, vets have often had little choice but to use metoclopramide preparations designed for human use - therefore effectively off-licence. This new preparation will allow vets to use a medication they know is of great benefit in treating dogs and cats, without taking all the additional precautions required for off-licence use, such as having clients sign consent forms.
The product can also be used in puppies and kittens. Severe vomiting in young puppies particularly can quickly lead to dehydration and depression, so it is vital to control the clinical signs and prevent fluid loss. Vomend will, according to the company, be particularly useful in this regard. As well as being an anti-emetic Vomend is also a pro-kinetic upper GI tract stimulant, so it is indicated for use in chronic nephritis, pyloric spasm and drug induced digestive intolerance.
Vomend will be available in 20 ml and 10 ml vials, providing greater flexibility over usage and stock control.
For further information on Vomend contact Eurovet on 01223 257933 or order direct from your wholesaler from early February.
Ed's note: The name. Is it just me? Wouldn't 'Tummyeaze' or something (anything) have been better?
Finding and settling into that first job is a particularly challenging time for a veterinary surgeon. Not only do you need to adapt to the practice environment and fit in with colleagues, but also gain a fast understanding of what's expected clinically, professionally, ethically and academically.
Recently retired after a 40-year career in practice, Clare is very well placed to give new grads useful advice. She's had six year's experience in mixed practice and 34 in small animal practice, both as an employee and an employer. She co-owned a small animal practice in Yorkshire which she developed with her veterinary partner from one surgery to a small animal hospital with four surrounding branch practices employing many vets and nurses over the years. She also spent 8 years on RCVS Council, giving her a deeper insight to the complexities of the wider profession.
What is perhaps a tad more unusual is that she writes from the perspective of someone who feels she has nothing to lose by being completely open and candid about her experiences.
Clare said: "I've really enjoyed my career and been fortunate enough to be able to balance it with family life, practice ownership and time on Council. But it hasn't always been easy. There are things I think I could have done better, and like everyone I've made some mistakes. I hope that by being open about these things, I might prevent others falling into the same traps.
The New Vet's Handbook covers employment options, interviews, mentoring, working with clients, patients and colleagues, consulting advice, dealing with euthanasia, record-keeping, veterinary standards, training and CPD, career options, professional skills and avoiding common pitfalls.
Clare added: "Although the purpose of the book is to help new grads settle in, especially those in smaller practices where a mentor may not always be readily available, I hope people will find it a funny, enjoyable read too."
The New Vet’s Handbook is available from 5m, priced at £24.95: http://www.5mbooks.com/the-new-vet-s-handbook-information-and-advice-for-veterinary-graduates.html
The Disciplinary Committee heard three charges against Dr Dhami, relating to events which took place while he was in practice at Vets4Pets in Market Harborough, Leicestershire.
The first charge against him was that, in November 2017, he used excessive force in kicking and stamping on a Staffordshire Bull Terrier he was treating.
The second charge was that, between in October and November 2017, he failed to pay adequate regard to the welfare of a Jack Russell in his care by leaving it in a sink without adequate reason and for an excessive period of time.
The third charge was that, between April and March 2018, he failed to have adequate regard to the welfare of a six-to-eight week old kitten, including providing bedding and warmth.
At the outset of the hearing Dr Dhami admitted to lightly kicking the dog, but denied forcefully kicking it and also denied that he had stamped on the dog, as well as denying the other two charges against him.
In considering the circumstances of the first charge, the Committee heard evidence from two of Dr Dhami’s colleagues stating that the dog had bitten him whilst he was cleaning its ears and, following this, he took the dog out of the consulting room, closed the door and whilst holding the dog’s lead then proceeded to kick her twice, knocking her along the floor both times, and then finally stamp on her when she was prone.
Dr Dhami disputed his colleagues' version of events and stated that he had only delivered two light kicks to the dog’s rump, that neither of these had made her fall to the floor and also denied in categorical terms that he stamped on the animal. Furthermore, he also denied the second and third charges against him.
In considering the evidence as to whether Dr Dhami kicked and stamped on the dog, the Disciplinary Committee found the evidence of his two colleagues to be credible and reliable, and so found all aspects of the charge proven.
Ian Green, chairing the Committee and speaking on its behalf, said: "For the avoidance of doubt, the Committee finds that the admitted kicks administered to [the animal] by the respondent were of significant force. The Committee rejects the respondent’s assertion that the admitted kicks amounted to mere taps on the backside. The Committee finds that the ‘stamping’ was also of significant force."
In regards to the second and third charges, the Committee was not satisfied that the charges had been proven by the evidence it heard and therefore dismissed them both.
Having found all parts of the first charge proven, the Committee then went on to consider whether or not Dr Dhami’s conduct amounted to serious professional misconduct, something that Dr Dhami, following the Committee’s decision on the facts, through his counsel, had admitted.
The Committee identified a number of aggravating factors, including the real risk of physical harm to the animal and the deliberate nature Dr Dhami’s conduct against the animal, committed in anger.
In mitigation, the Committee accepted that this was an isolated incident and that Dr Dhami had been bitten and was in pain. The Committee therefore found that Dr Dhami’s admission of serious professional misconduct was ‘properly and prudently made’.
The Committee then considered what sanction to impose on Dr Dhami. In doing so it took into account some of the written testimonials and character witnesses called on behalf of Dr Dhami. The Committee was also satisfied that Dr Dhami had had a hitherto long and unblemished career, that he had apologised to colleagues immediately after the incident and that, since the events, he had continued to work as a veterinary surgeon without any problems.
In relation to insight about the event, the Committee accepted Dr Dhami had provided some evidence of reflection, in that he admitted kicking the dog and accepted that this conduct, once found proven, amounted to serious professional misconduct.
The Committee decided that suspending Dr Dhami from the Register for four months would be the most proportionate sanction.
Ian Green concluded: "Having regard to all the matters urged by way of mitigation, and having taken into account all the evidence that it has heard, the Committee is satisfied that a period of suspension is sufficient in this case to protect the welfare of animals, maintain public confidence and to declare and uphold proper standards of conduct."
Dr Dhami has 28 days from being informed of the outcome of the hearing in which to make an appeal to the Privy Council.
The Disciplinary Committee of the Royal College of Veterinary Surgeons last week directed that the name of a man who had been illegally practising as a veterinary surgeon in the North West of England be removed from the RCVS Register, having found him guilty of fraudulent registration.
In March 2008, Russell Lewis Oakes had been charged with fraudulent entry onto the Register of Veterinary Surgeons, on the basis that he had (either (A) knowingly, or (B) unknowingly) submitted a fake degree certificate and letter of 'good standing' from Murdoch University, Australia. Mr Oakes agreed that the hearing could proceed in his absence provided the Committee confined itself to consideration of charge B alone.
The hearing commenced on 18 April 2008, but the Committee decided to adjourn, as Mr Oakes was also subject to a police investigation which required that the hearing be held in private. The Committee felt that it was in the public interest for an open hearing to take place in respect of both charges at a later date. Mr Oakes' bail conditions prevented him from practising as a veterinary surgeon at this time.
On 16 October 2009, Mr Oakes was convicted at Liverpool Crown Court, on a guilty plea, of a substantial number of offences, including those under consideration by the Committee: he was sentenced on 11 January 2010 to two years in prison.
The RCVS Disciplinary Committee's hearing resumed and concluded on 5 February 2010. Mr Oakes was not present.
The Committee was provided with evidence from RCVS staff regarding the registration process, and received statutory declarations from representatives at Murdoch University. The latter confirmed that signatures on the certificate submitted by Mr Oakes were fake and that there had never been a student with his name at the University. Furthermore, a letter purporting to be one of support from Professor Edwards of Murdoch University contained text he would not have written and was signed with a false signature.
The Committee was also provided with evidence from equine veterinary surgeon Seamus Miller, who had become suspicious of Mr Oakes' qualifications and membership of the College. He outlined incidents which had cast doubt on Mr Oakes' competence. Mr Miller's complaint had initiated enquires which led to the charges against Mr Oakes by the College, and the Committee recorded its commendation of Mr Miller, and his colleagues.
Having found that Mr Oakes knowingly submitted fraudulent registration documents, the Committee was bound, under Sections 14 and 16 of the Veterinary Surgeons Act 1966, and paragraph 17 of the 2004 Rules, to direct that his name be removed from the Register.
Alison Bruce, Chairman of the Disciplinary Committee, said: "Even if it retained any discretion by virtue of Section 16 of the Act in respect of sanction, the Committee would have had no hesitation in directing Mr Oakes' name to be removed from the Register in this case. This was a deliberate and dishonest offence by a man without the necessary qualifications to practise as a veterinary surgeon, and it had the effect of exposing members of the public to his fraud, and their animals to harm."
The College has revised its registration procedures in the light of this case, and now requests that all registrants produce original copies of certificates and letters of 'good standing' at the registration ceremony.
Alphazium TT contains alphalactalbumin and magnesium, which, according to the company, targets the three main neurological pathways involved in the regulation of mood and emotional balance.
TVM says Alphazium TT is highly palatable, so it can be administered as a treat, making the process stress free for veterinary staff, pets and pet owners.
TVM UK’s product manager Will Peel said: "Behavioural problems are becoming increasingly common in cats and dogs and are these problems are likely to get worse with pet owners going back to work as lockdown measures lift, which could cause further stress and anxiety in pets.
"Alphazium TT can help owners address these problems whilst being highly palatable – therefore also reducing the stress of tablet administration all-round."
For more information and support materials, visit: https://www.tvm-uk.com/alphaziumtt/2520/ or contact your TVM UK Territory Manager.
Effipro Duo contains fipronil to kill adult fleas and ticks, and pyriproxyfen, an insect growth regulator, to sterilise adult fleas and inhibit the immature life stages. It provides three months protection against flea life cycle completion.
The product is presented in Effipro’s patented ‘drop-lock’ pipette, designed to ensure that the solution is released only when the owner is ready.
Effipro Duo is offered in packs of 4 pipettes and in a 24-pipette dispensing pack to suit practices offering health plans.
Product Manager Kate Woolley MRCVS said: "Because Effipro Duo targets not just the adult fleas on the pet but also the key developmental stages in the flea life cycle often found in the home, it represents an integrated and easy-to-use solution, both for on-animal flea and tick control and for long-lasting protection of the home environment.
"Household flea infestations are common all year round and experts agree that the combination of an adulticide and an insect growth regulator is the most effective way for owners to protect their homes from this unpleasant problem¹. For complete flea control in the home, we recommend that it is used in conjunction with Indorex®, the UK’s no. 1 household flea spray².
"Virbac offers one of the most extensive parasiticide ranges on the market and we believe Effipro Duo will provide a popular addition, offering owners long-lasting protection from fleas and ticks for their cats and dogs, while helping practices to retain vital parasite control sales in-house."
References
Mr Wood was removed from the Register in 2018 after being convicted of posessing indecent images of children and made subject to a Sexual Harm Prevention Order for five years.
Mr Wood first applied to rejoin the Register in 2020 but his application was rejected.
At the outset of his second application last month, Mr Wood’s counsel argued that he is professionally competent to be restored, that he had strong mitigation for his offending, that he had consistently and repeatedly expressed and demonstrated profound remorse, that he posed a low risk of re-offending, that he had proactively engaged with the Probation Service and voluntary counselling to gain further insight into his offending, and that he had completed his community sentence and was no longer subject to any of the court orders arising from his conviction.
The Committee then weighed up whether Mr Wood had accepted its original findings in 2018, the seriousness of the offences, whether he demonstrated insight, protection of the public and the public interest, the future welfare of animals should he be restored to the Register, the length of time off the Register, Mr Wood's conduct since he was removed and evidence that he had kept up-to-date with veterinary knowledge, skills and practice.
Dr Kathryn Peaty MRCVS, chairing the Committee and speaking on its behalf, said: “The Committee is satisfied that Mr Wood has done everything required of him in order to be able to satisfy the Committee that he is fit to be restored to the Register.
“At the last application in June 2020, he was unsuccessful largely because of the outstanding ancillary Court Orders that did not conclude until early 2023. Those Orders have now concluded
“He has shown significant insight into his offending behaviour. He has been proactive in his rehabilitation and taken significant steps to ensure there would be no repetition.
“He has a small, but strong, network of people around him who appear to genuinely care about him and support him. He has worked hard at maintaining his skills and knowledge, in so far as he has been able to in light of not being able to practise as a veterinary surgeon.
“He is thoughtful and realistic about his prospects going forward. His responses to questions about addiction were appropriate and persuasive. He has expressed genuine remorse and there is, in the Committee’s view, a public interest in allowing him to be restored to the Register.”
www.rcvs.org.uk/disciplinary
Thiamacare contains 10 mg/ml thiamazole, which is double the concentration of Thyronorm, for a lower dose volume.
Animalcare highlights research which shows that 87.4% of owners prefer liquid medications for their cat1, and that cats find liquid presentations more palatable2.
James Beaumont from Animalcare said: "With the lowest dose volume available, we believe Thiamacare will make the medical management of this condition easier through improved cat acceptance and better owner compliance."
Thiamacare's dosing syringe is marked with a single scale in 1.25 mg increments to facilitate precise dosing in response to total T4 measurement values. The scale does not need converting when switching from other brands or formulations.
Animalcare has developed a range of supporting materials to encourage the use of Thiamacare as the preferred choice for feline hyperthyroid medical management. They include social posts and a post-prescription leaflet to help veterinary teams support owners, particularly through the stabilisation phase post-diagnosis.
A short webinar offering top tips for treating feline hyperthyroidism from feline Specialist Dr Caney will also be available later in October. These resources will all be available at www.the-pac.co.uk.
Amy Scott MRCVS, Boehringer Ingehlheim’s performance horse portfolio manager, said: "Arti-Cell Forte is the first 'ready-to-use' stem cell-based product to be licensed in any veterinary species, and the only stem cell treatment to contain induced cells, representing a significant leap forward in both stem cell therapies and medicine as a whole.
"Arti-Cell Forte contains stem cells that have been chondrogenically induced and therefore primed to develop into the cartilage cell lineage. Studies have shown that chondrogenically induced stem cells demonstrate an enhanced clinical outcome compared to un-induced stem cells in the treatment of joint disease in horses¹."
"This makes Arti-Cell Forte a highly targeted and effective treatment for cartilage damage associated with degenerative joint disease."
Arti-Cell Forte is available direct from Boehringer Ingelheim to veterinary practitioners.
It needs to be stored at ultra-low temperatures to maintain its two year shelf life from manufacture, either frozen at -70 ⁰C to -90 ⁰C (dry ice, -80 ⁰C freezer) or -196 ⁰C (liquid nitrogen) until immediately prior to injecting.
The company is providing full training on storage and administration via face-to-face CPD at practice meetings or specific CPD events*.
For more information, contact your local territory manager or ring Boehringer's Technical Services Team on 01344 746957, or email vetenquiries@boehringer-ingelheim.com
Reference
The VetCompass programme studied 10,313 English Cocker Spaniels from an overall sample of 336,865 UK dogs of all breeds under first opinion veterinary care during 2016.
English Cocker Spaniels made up 3.1% of all dogs, showing ongoing high popularity of this breed as a UK companion animal.
The most common disease was periodontal disease, diagnosed in 20.97% of English Cocker Spaniels each year.
In second place was otitis externa (10.09%), followed by obesity/overweight (9.88%), anal sac impaction (8.07%), diarrhoea (4.87%), and aggression (4.01%).
The order of these top disorders in English Cocker Spaniels was similar to those previously reported in dogs overall; however, the frequency of each disorder was generally higher in English Cocker Spaniels than the general dog population, possibly because several of these conditions are related to the longer ears and looser skin on English Cocker Spaniels.
Researchers say these results suggests that English Cocker Spaniels can be considered a typical dog in many respects, but with higher risk of some disorders related to their specific body shape.
Aggression was found to be relatively common in English Cocker Spaniels, although the frequency differed depending on the sex and coat colour of the dogs: aggression was more common in males than females, and in single-coloured than multi-coloured dogs.
The risk of aggression also varied widely between the four most common single-coloured coat colours: golden-coloured dogs showed the highest frequency of aggression (12.08%), followed by red (6.52%), black (6.29%), and liver (4.33%).
Additional findings include:
Karolina Engdahl, Epidemiologist at the Swedish University of Agricultural Sciences and lead author of the paper, said: “English Cocker Spaniels are popular family dogs and can make fantastic pets.
"However, we found that aggression was relatively common in the breed, especially in golden-coloured dogs.
"This highlights the importance of focusing good breeding on behavioural as well as physical health, and that behavioural-related problems should be a key area for veterinary-owner discussions.”
Dan O’Neill, Associate Professor in Companion Animal Epidemiology at the RVC, co-author of the paper, said: “Everyone who loves dogs just wants their animals to live long and happy lives.
"This study provides the data to help owners to understand that preventing dental, ear, weight and anal sac problems can go a long way to helping English Cocker Spaniels to enjoy a better life.
"It really can be that simple.”
Meantime, the school was given a “conditional accreditation” for its degree, as it had met only 27 of the 77 RCVS accreditation standards.
The visitation was conducted by an accreditation panel comprising representatives from veterinary academia and clinical practice, as well as student and international representatives.
As part of the accreditation process, the panel considered documents and records, discussions and interviews with students and faculty members, a tour of the teaching facilities, and meetings with other stakeholders.
Based on the evidence, the panel agreed 55 recommendations for improvement which were then discussed, alongside the formal response from the Department, by the RCVS Primary Qualifications Subcommittee (PQSC), the body responsible for considering accreditation reports and making recommendations to Education Committee.
By contrast, the accreditation visit to the University of Bristol this year generated just one recommendation, likewise the visit to the University of Surrey last year.
Due to the unusually high number of recommendations and concerns about the delivery of the Cambridge degree, PQSC recommended that the programme receive conditional accreditation for 10 months, which was then agreed by Education Committee.
An RCVS spokesperson said: “Following careful review of the evidence, during the Committee’s detailed discussions, it was unanimously agreed that the number of standards not currently being met, which extended across all domains, meant that the Committee made the difficult decision to grant conditional accreditation.
“In reaching a decision and timeframe, given the problems identified, and the impact these will have on student learning and experience, Education Committee members firmly agreed on the need to help the vet school support both existing students on, and future applicants to, the Cambridge veterinary programme.”
“At the next visitation in September 2025, a panel will consider the evidence submitted and then a decision will be made on the future status of the degree.”
"In the meantime, we recognise that both students and staff might have concerns about this outcome, so we remain able and very willing to work closely with the Department in the coming weeks to ensure it has appropriate support plans in place.”
The full list of recommendations, suggestions and commendations for Cambridge can be found at: www.rcvs.org.uk/visitations.
Ubroseal is licenced for the prevention of new intramammary infections throughout the dry period. In cows considered likely to be free of sub-clinical mastitis, the product can be used on its own in dry cow management and mastitis control.
Boehringer's veterinary adviser, Kath Aplin said: "Ubroseal features a flexi-cap to reduce the risk of teat canal damage and its unique longer plunger makes application more ergonomic and significantly easier for the farmer."
The launch coincides with the publication of a statement by an expert group convened by Boehringer1 which recommends the administration of an internal teat sealant at drying off to all cows on all farms.
For more information, contact: vetenquiries@boehringer-ingelheim.com.
The hearing proceeded in Ms Kay’s absence as she failed to attend. The Committee heard a number of charges relating to her practising while under the influence of alcohol, breaching undertakings to the College to abstain completely from alcohol, alleged serious clinical failings in relation to the treatment of two dogs, Izzy and Alfie, and making disparaging remarks to a client about other veterinary surgeons (the complete list of charges can be found on the College’s website: www.rcvs.org.uk/concerns/disciplinary-hearings/).
In relation to the first charge, (that in September 2016, while a locum veterinary surgeon at Haven Veterinary Surgeons Group, Great Yarmouth, she was under the influence of alcohol), the Committee heard from a veterinary nurse at the practice who told how on different occasions Miss Kay had appeared to need more assistance than expected, was overly friendly in speaking to clients, was unable to prepare a syringe correctly, and finally, on 14 September 2016, was found asleep in the car with an open can of alcohol by her feet. The Committee also heard from a number of other witnesses from the Haven Veterinary Surgeons Group who also provided evidence of Ms Kay’s behaviour on the day in question. Following deliberations, the Committee found the first charge to be proved.
The second charge related to the breaching of undertakings which Ms Kay had given to the College to the effect that she would abstain completely from alcohol. When samples were taken on 3 August 2017, however, it was found that she had been consuming alcohol in the recent past. The Committee was therefore satisfied that the second charge was proved.
The Committee then turned to the third charge, that in March 2017 Ms Kay had displayed a number of clinical failings when performing surgery on a cocker spaniel, Izzy, belonging to Mrs Debbie Coe. The Committee found the majority of the charges proved, amongst others that she failed to obtain informed consent for surgery, performed surgery in her own home when it was not registered as a veterinary practice and it was not possible to ensure sterility, and that she failed to provide suitable post-operative analgesia to Izzy.
The College then turned to the fourth charge, which concerned her treatment of Mrs Coe’s other dog, Alfie, a Miniature Schnauzer. The charge was that in March 2017, Ms Kay euthanased Alfie in an inappropriate manner, and used a controlled drug without having a registered veterinary premise from which to dispense it. After hearing from an expert witness the Committee found the charges proved.
Finally, the Committee heard evidence relating to the fifth charge, namely that in or around July 2016, Ms Kay made disparaging remarks to Mrs Coe about other veterinary surgeons who had treated Alfie, and that between 17 March and 31 March 2017 she had sent inappropriate texts and voicemail messages to Mrs Coe about the treatment of her dogs and payments owed in relation to this. The Committee thought there was not enough evidence in relation to the voicemails, but found the remainder of the charge proved.
Taking all into account, the Committee found that Ms Kay’s conduct had fallen far short of the standard expected of a member of the veterinary profession and concluded that her conduct clearly amounts to disgraceful conduct in a professional respect.
Alistair Barr, chairing the Committee and speaking on its behalf, said: "The Committee considered that the only appropriate sanction is that of removal from the Register. Such a sanction is required to protect animals and to send a clear message to the Respondent, and to all veterinary surgeons, of the unacceptability of the conduct identified in this case. Such conduct undermines public confidence in the profession and fails to uphold proper standards of conduct and behaviour.
"Accordingly, the Committee has decided that removal from the Register is the only appropriate and proportionate sanction in this case."
Ms Kay has 28 days from being informed about the Disciplinary Committee’s decision to make an appeal to the Privy Council.
The main aim of the campaign is to persuade anyone thinking of getting a puppy that they should always see the animal at least once whilst it is still dependent on its mother, before they buy. That way, they'll be able to reassure themselves that they have seen the real bitch and the environment in which the puppy was bred. It will also help prevent impulse purchases.
In addition, the campaign aims to raise awareness in the veterinary profession, so that veterinary surgeons are giving this same advice to their clients.
To that end, the campaign highlights the RSPCA 'Sold a pup' report which showed that over 400,000 pups are bred for the UK market each year by unlicensed establishments, and imports from Europe have increased to an estimated 30,000 in 2015, following the change in the PETS scheme in 2012.
The campaigners say that many of these puppies are bred in truly awful conditions, often with little or no human contact, before being taken taken from their mothers too early and transported often hundreds or thousands of miles to be sold as 'family' pets. Many will need veterinary care to deal with infections, inherited issues and behavioural problems.
The campaign faces a big challenge. In the Kennel Club PAW survey 2014, 41% of people who bought a puppy didn't see the bitch and 51% didn't see the environment where the litter was bred.
To spread the word, veterinary surgeons, veterinary nurses and pet owners are being asked to take a pouting selfie with their dog and post it on social networks like Facebook, with the hashtags #PoutForPuppies #SeeThemSuckling, linking to the campaign website: https://seethemsuckling.com
Research shows that over 60% of cast-treated pets get additional injures, such as pressure sores, from traditional plaster casts1.
The new cast is designed to tackle these issues with anatomically shaped bi-valve splints that are based on 30,000 3D scans of animal limbs.
Upets TLC products are made from FDA and CE approved Woodcast material used in human casting and splinting.
Bandages, padding and tape are replaced with a soft, self-cohesive Unitex fabric that passes moisture and dries fast.
TLC products are engineered for easy destabilisation by removing parts of the splint, and the same product can be used throughout the whole treatment.
Orthopets, a subsidiary of the materials company Dassiet, says that breathable, lightweight materials combined with the anatomical fit help prevent sores and restore normal position and movement of the limb.
OrthoPets founder Martin Kaufmann said: “The common cast is very problematic, but we've lacked better alternatives. Now, with the Dassiet supermaterials and OrthoPets’ vast experience in veterinary biomechanics we have re-engineered the common cast.
"Upets TLC is anatomical and safe. It’s stress-free for both the vet and the pet. It brings veterinary casting to the modern day and offers a better standard care option for all vets and orthopaedic surgeons out there.”
"Sores, pain and stiffness are always on the horizon with casting. But if we take the cast off too early, the leg can be injured again because of lack of proper support. UPETS tackles these problems all at once. I find it easy to apply the pre-shaped casts even for very small or large dogs and make adjustments if needed. I can watch my patients walk off the clinic normally with their cast, knowing they can wear it safely until fully healed. We see significant and immediate improvement in patients compared to the common cast”, says Dassiet Chief Veterinarian Jouni Niemi, who oversees the clinical research of UPETS.
For more information, visit: www.upets.vet/TLC
Zoetis, maker of Zylexis, is highlighting a new review published in Veterinary Immunology and Immunopathology, which has concluded that immune-modulators may provide a valuable contribution to the reduction of some equine respiratory diseases
The study reviewed the immune-modulators Parapoxvirus ovis and Propionbacterium acnes for the prevention of respiratory disease and other infections in the horse.
Parapoxvirus ovis (iPPVO) and Propionibacterium acnes (P.acnes) are currently used in equine medicine as immune-modulators for prophylactic treatment or adjunct to conventional therapy in order to improve immune defences, to prevent or treat infectious diseases. Their mode of action relies on a non-antigen-specific interaction with the innate and/or adaptive immune responses. iPPVO stimulates and regulates cytokine secretion by a number of leucocytes, while P. acnes acts primarily through activation of macrophages.
The review, conducted by Romain Paillot of the Animal Health Trust, Centre for Preventive Medicine, Newmarket, examined current scientific literature and reports on the use of immune-modulators in horses, particularly for the prevention or treatment of equine respiratory disease.
Stress factors such as weaning, transport and co-mingling predispose horses to infection and increase susceptibility to respiratory pathogens such as Streptococcus zoopidemicus and EHV-1/4. In the past 15 years iPPVO has been tested against several equine infectious respiratory diseases.
The review examined the results of studies on the beneficial use of iPPVO to limit the severity of respiratory infectious diseases in young horses, one of which evaluated the use of iPPVO for protection in yearlings exposed by contact challenge to EHV-1 or EHV-42,3,4. Yearlings treated with iPPVO were co-mingled with horses experimentally infected with EHV-1 and the trial was repeated with horses infected with EHV-4. Horses treated with iPPVO showed a 40% reduction in disease severity in the EHV-1 study and a 61% reduction in the EHV-4 study.
Further studies showed significantly increased frequency of recovery in horses with clinical signs of respiratory disease that had been treated with P. acnes. The decrease in disease severity was also significantly improved in the treated groups5,6.
Romain Palliot concluded: "Non-specific immune-modulators such as iPPVO or P. acnes may not provide protection against direct infection or transmission of respiratory pathogens but they seem to contribute to the reduction of the disease severity, subsequently reducing the frequency of complications and improving the rate of recovery."
For the research, Miele commissioned independent market research firm Sapio to interview 1000 pet owners and 100 UK-based vet practices.
Veterinary practices have good reason to worry about complaints: the research showed that 89% of veterinary clients would be quick to tell others if they were dissatisfied with any aspect of the practice or care received. 63% said they would air their grievances on an online review site and 60% said they'd share their views on social media.
Those figures appear to be borne out by the fact that only 10% of vets said they had not seen any negative comments online about their practice.
Interviews with pet owners also found that the top five factors to affect a practice's reputation were: standard of care, a clean and hygienic environment, good customer service, the cost of treatment and waiting times, in that order.
64% of vets agreed that practice hygiene has become increasingly important with cleanliness of staff uniforms and waiting rooms among the first things that customers notice.
The suitably spruce Sam Bailey (pictured right), Sales & Marketing Director for the Professional division of Miele said: "Vet practices are increasingly coming under the same online scrutiny as hotels and restaurants and are being judged on everything from customer service through to staff appearance and waiting times.
"As our research results show, vets are already concerned about their reputations and it’s not just customer service and care outcomes that matter to pet owners, they also have high expectations when it comes to the practice environment too and are looking at cleanliness, hygiene and staff appearance.
"Through our network of approved partners we are working with more and more vet practices throughout the UK to ensure their on premise laundries not only meet WRAS regulations but also support their standards on hygiene, infection control and cleanliness."
Virbac has launched of Bovigen Scour, an emulsion for injection into cattle which reduces the severity of diarrhoea caused by bovine rotavirus, bovine coronavirus and enteropathogenic E.coli F5 (K99).
Bovigen Scour works by actively immunising pregnant cows and heifers and providing passive immunity to their calves via colostrum. According to the company, the vaccine also helps to reduce the shedding of virus by calves infected with bovine rotavirus and coronavirus.
Virbac says a key benefit of Bovigen Scour is the vaccination protocol which offers a large window for injection, making it easier for vaccination planning. The primary course is administered in two shots, with first dose between 12 and 5 weeks before calving and the booster 3 weeks later. The annual booster is then due between 12 and 3 weeks before calving is expected. The vaccine is presented in two sizes: 15ml (5 doses) and 90ml (30 doses). The dosage per cow is 3 ml and the withdrawal time is nil in milk.
Virbac Large Animal Product Manager Brigitte Goasduf MRCVS said: "Bovigen Scour offers farmers flexibility and ease of use. The flexibility it gives in terms of scheduling the primary course and booster is particularly important and is highly relevant for beef cattle farmers as it can be difficult to know exactly when a cow is likely to calve and it is vital not to miss the vaccination window.
"Bovigen Scour is also convenient to give because of the small volume of emulsion and because the injection is given intramuscularly. Its launch extends our large animal vaccine range, which includes Gudair, for the active immunisation of sheep and goats against Mycobacterium avium subspecies paratuberculosis (Map)."
This latest incarnation of the FECPAKG2 is now a battery-powered and wi-fi enabled. This means it can pair with smartphones, tablets and laptops, allowing samples to be uploaded, analysed and results received, virtually anywhere.
Tabitha Allen from Techion said: "The technology allows internet connected and image-based FEC testing to be carried out literally on the job.
"While the current system is able to return results rapidly, samples need to be uploaded via a computer. The upgrade will therefore give users more flexibility, allowing samples to be processed away from the office."
"Samples are then analysed by trained online technicians so we can confidently provide accurate results, which can then help farmers make informed decisions when it comes to worming.
"The new upgrade now includes a digital microscope that enhances image quality further, making it quicker and easier than ever before to provide these accurate results.
For more information, visit: www.techiongroup.com or ring: 01970 821 918
The new maternity policy will offer enhancement at 100% of full pay for 10 weeks, and 50% of full pay for a further 10 weeks, without any clawback provision should mothers decide not to return to CVS after their leave.
As part of the Time To Change Pledge, CVS will submit a plan for introducing evidence-based interventions and policy to help its employees work in ways that promote positive mental wellbeing.
CVS's plan includes the appointment of 250 Wellbeing Champions who will be trained in first aid for mental health. The company also plans to roll out further training on managing stress and mental health issues for line managers in 2020.
Richard, pictured right, said: "We are proud to be the first major veterinary employer to sign the Time to Change Pledge. The CVS wellbeing working party have made much progress in the last 12 months delivering our plan which has been formalised through participating in the Time to Change pledge.
"We recognise that the pressures in our industry are significant and unique, and that there’s more work to do. We remain committed as a company and wellbeing working party to changing the way we all think and act about mental health in the workplace for the better."
Suvaxyn PRRS MLV offers the earliest piglet vaccination from the first day of age, securing immunity before the risk period which lasts until the end of the fattening. Pig protection is established 28 days after vaccination, and lasts for 26 weeks after vaccination in fattening pigs, and 16 weeks after vaccination in gilts and sows. Zoetis says the vaccine reduces viremia and nasal shedding of the virus.
Monica Balasch, Associate Director, Global Biologicals Development at Zoetis said: "In Europe, Porcine Reproductive and Respiratory Syndrome is known for severe impacts on reproduction including lowering birth rates, increasing abortion, stillbirth, mummified, as well as weak live-born piglets, and death.
"In clinical studies conducted with Suvaxyn PRRS MLV, we found excellent results vaccinating pigs from the first day of age. It is safe to be used as the earliest protection in piglets, and to protect the whole herd against PRRS, as it is also safe for use in gilts and sows.
"The new vaccine represents a flexible alternative to allow for new customized PRRS control programs developed by veterinarians for producers."
Alvaro Aldaz, Director, Commercial Development and Innovation, Swine, at Zoetis said: "We are excited to bring this innovative vaccine to Europe. Suvaxyn PRRS MLV has been developed using a very innovative vaccine technology which brings swine veterinarians a new advanced PRRS control tool.
"As well reducing viremia, nasal shedding and lung lesions in fattening pigs, the vaccine has been proven to overcome maternal immunity, which increases the efficacy of the vaccine when given to piglets during the first days of life. Additionally, it allows veterinarians for use PRRS mass vaccination within the claim; mass vaccination has become more and more popular in several European countries."
Suvaxyn PRRS MLV is a veterinary vaccine that contains a European PRRS virus strain (Genotype 1) that has been grown and attenuated in a uniquely modified cell line developed by Zoetis.
Jay Calvert, Research Director, VMRD Global Biologicals Research at Zoetis said: "Suvaxyn PRRS MLV is safe based on true loss of virulence, and not based on a temporary reduction in ability to replicate in macrophage cells in the lung of the pig."
Zoetis says the efficacy of Suvaxyn PRRS MLV is supported by a comprehensive program of clinical studies reviewed by the European Medicines Agency and included in the regulatory procedure approved by the European Commission in August 2017.
The European public assessment report is available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/veterinary/004276/WC500235212.pdf
The company says the most common side effects with Suvaxyn PRRS MLV (which may affect more than one in 10 pigs) are a short-lived increase in body temperature (0.5°C on average and up to 1.4°C individually) within four days of vaccination, and in sows local reactions in the form of swellings which resolve without treatment within five to 32 days.
Royal Veterinary College research, published in the journal PLOS ONE, has revealed that 1 in 4 cases of Diabetes Mellitus in domestic cats are caused by excess secretion of pituitary growth hormone.
According to the researchers, this is much more common than previously thought. Furthermore, they say that cats with this condition are easily misdiagnosed as having primary (type 2) diabetes mellitus but do not respond to the standard treatment to that condition, resulting in increased morbidity and ultimately leading to euthanasia on welfare grounds.
Researchers collected data between 2003 and 2011 on cats treated at vet practices across the UK, to estimate the prevalence of hypersomatotropism or acromegaly in the largest cohort of diabetic cats to date and look how easy this is to recognise.
Findings revealed that the presence of Diabetes Mellitus in 1 in 4 domestic cats can be explained by hypersomatotropism, which is caused by a pituitary benign tumour and can be effectively treated by one operation in specialist centres.
However only 24% of clinicians who submitted samples suspected that this was the case, as most hypersomatotropism cats did not display typical signs, instead displaying symptoms indistinguishable from cats with primary (type 2) Diabetes Mellitus. This suggests that hypersomatotropism screening should be considered when treating diabetic cats.
Lead researcher, Dr Stijn Niessen from the Royal Veterinary College, said: "It has been common practice to automatically suspect a cat with Diabetes Mellitus to be suffering from a form of diabetes akin to human type 2. The current study suggests that this is an oversimplification. Approximately one in four of assessed diabetic cats were actually found to be suffering from hypersomatotropism-induced Diabetes Mellitus, which requires specific treatment and manifests itself very differently as it develops.
"Interestingly, only a small proportion of clinicians reported they strongly suspected acromegaly to be present on the basis of the clinical picture. These data therefore highlight the need for veterinarians working with the spontaneously diabetic cat to consider routinely screening for the presence of hypersomatotropism-induced Diabetes Mellitus, given the significant clinical consequences of its presence.
"Should the hypersomatotropism be diagnosed and treated with one operation, most cats will enter a state of diabetic remission. If it remains undiagnosed, diabetic cats tend to be difficult to regulate glycaemically which often results in euthanasia, or in the long-term, they will suffer from other growth hormone-induced negative conditions such as heart disease, as well as central nervous system problems."
Evaluation of serum fructosamine was offered free of charge for all diabetic cats attending any veterinary practice in the UK from October 2003 till April 2011. Veterinary surgeons were asked to record clinical data about the patient, including age, breed, gender, current body weight, current administered insulin dose and whether they clinically suspected acromegaly/ hypersomatotropism. Diabetic cats were screened using serum total insulin-like growth factor-1, followed by further evaluation through pituitary imaging and/ or histopathology.
In total, 1221 diabetic cats were screened; 319 (26.1%) had a blood IGF-1 suggestive of hypersomatotropism. Of these cats a subset of 63 (20%) underwent pituitary imaging and 56/63 (89%) had a pituitary tumour on computed tomography; an additional three on magnetic resonance imaging and one on necropsy. These data suggest a positive predictive value of serum IGF-1 for hypersomatotropism of 95%, suggesting the overall hypersomatotropism prevalence among UK diabetic cats to be 24.8%.
The paper also suggests that although great opportunities exist for comparative research between primary (type 2) diabetes in cats and humans, researchers should exercise caution in light of these new findings.
Stijn added: "The similarities between feline and human type 2 diabetes emphasise great opportunities for valuable comparative research benefiting all species into this major disease, which is fast becoming a global epidemic. However our latest research proves that there is a need for more regular hypersomatotropism screening, to identify the root cause of diabetes in domestic cats before samples are used, so as not to corrupt results."
Lynne was instrumental in creating the Linnaeus business in January 2015, and then growing it to the point where it now has 145 veterinary practices across the UK.
Lynne will be staying on as a consultant for Mars Petcare, which acquired Linnaeus in June 2018. She said: "As much as I would love to be part of the continuing journey and success of Linnaeus, I feel it is right for me to step back from the total time commitment required to be a CEO."
Paul Coxon, Linnaeus Chief Financial Officer, said: "The Linnaeus Group’s achievements under Lynne’s leadership cannot be underestimated. Since 2015, there have been numerous development milestones and significant growth as we have welcomed a number of highly-regarded referral centres and exceptional first opinion brands to the Linnaeus family. Lynne leaves us with a great legacy and a very bright future."
Linnaeus is due to make an announcement on Mrs Hill’s successor shortly.